Researchers at Numis Didn’t Change their “Buy” rating for Abzena Plc (LON:ABZA). The Price Objective is GBX 62.00; Seacoast Banking of Florida (SBCF) Shorts Decreased By 36.89%

Abzena plc (LON:ABZA) Logo

In analysts report shared with investors on today, Numis reaffirmed their “Buy” rating on Abzena Plc (LON:ABZA)‘s stock. The PT gives a potential upside of 217.95% from firm’s current price.

Seacoast Banking Corporation of Florida (NASDAQ:SBCF) had a decrease of 36.89% in short interest. SBCF’s SI was 458,900 shares in April as released by FINRA. Its down 36.89% from 727,200 shares previously. With 206,200 avg volume, 2 days are for Seacoast Banking Corporation of Florida (NASDAQ:SBCF)’s short sellers to cover SBCF’s short positions. The SI to Seacoast Banking Corporation of Florida’s float is 1.09%. The stock decreased 1.18% or $0.32 during the last trading session, reaching $26.81. About 212,762 shares traded. Seacoast Banking Corporation of Florida (NASDAQ:SBCF) has risen 12.55% since April 16, 2017 and is uptrending. It has outperformed by 1.00% the S&P500.

Seacoast Banking Corporation of Florida operates as the bank holding firm for Seacoast National Bank that provides community banking services to the commercial, small business, and retail clients in Florida. The company has market cap of $1.26 billion. It offers various transaction and savings deposit products; secured and unsecured loan products, including revolving credit facilities, letters of credit and related financial guarantees, and asset based financing; and securities and annuity products. It has a 27.08 P/E ratio. The firm also provides trust and asset management services to retirement plans, firms, and individuals; treasury management services; brokerage services; and Internet and mobile banking services.

Among 9 analysts covering Seacoast Banking Co. of Florida (NASDAQ:SBCF), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Seacoast Banking Co. of Florida had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by SunTrust given on Tuesday, November 28. The stock of Seacoast Banking Corporation of Florida (NASDAQ:SBCF) earned “Hold” rating by Hovde Group on Wednesday, January 3. The stock of Seacoast Banking Corporation of Florida (NASDAQ:SBCF) earned “Buy” rating by SunTrust on Monday, February 13. As per Tuesday, January 30, the company rating was maintained by Guggenheim. The firm has “Outperform” rating given on Wednesday, November 30 by Raymond James. The firm has “Sell” rating by Zacks given on Thursday, August 27. SunTrust initiated Seacoast Banking Corporation of Florida (NASDAQ:SBCF) rating on Monday, April 11. SunTrust has “Neutral” rating and $17 target. The firm has “Market Perform” rating by Hovde Group given on Tuesday, September 6. Wood maintained the stock with “Market Perform” rating in Friday, August 28 report. The rating was upgraded by Hovde Group on Wednesday, May 11 to “Outperform”.

Investors sentiment decreased to 1.48 in Q4 2017. Its down 0.12, from 1.6 in 2017Q3. It fall, as 8 investors sold Seacoast Banking Corporation of Florida shares while 38 reduced holdings. 26 funds opened positions while 42 raised stakes. 34.32 million shares or 3.56% more from 33.14 million shares in 2017Q3 were reported. Neuberger Berman Group Incorporated Limited Liability holds 0% or 48,500 shares in its portfolio. Metropolitan Life Insur has 0% invested in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). The New Jersey-based Highlander Mngmt Limited Company has invested 0.6% in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Moreover, Natl Invest Service Wi has 0.56% invested in Seacoast Banking Corporation of Florida (NASDAQ:SBCF) for 23,295 shares. Lord Abbett And Llc has 0.07% invested in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Citigroup, New York-based fund reported 9,886 shares. Driehaus Cap Management Lc accumulated 258,150 shares. Rhumbline Advisers accumulated 40,787 shares or 0% of the stock. Mendon reported 2.55% of its portfolio in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). Banc Funds Communications Lc, Illinois-based fund reported 877,669 shares. Globeflex L P reported 4,827 shares. California Public Employees Retirement Systems reported 48,869 shares stake. State Of Wisconsin Inv Board owns 23,000 shares. Tower Cap Ltd Liability Co (Trc) has 1,181 shares for 0% of their portfolio. Cubist Systematic Strategies Limited Co invested in 0.02% or 13,227 shares.

Since March 7, 2018, it had 0 insider buys, and 1 sale for $175,616 activity. Another trade for 6,407 shares valued at $175,616 was sold by Goldman Roger.

Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. The company has market cap of 40.70 million GBP. It provides antibody drug conjugate linker, antibody humanization, and protein deimmunisation technologies and solutions, which include phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to its test in clinical trials; antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and antibody drug conjugates, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging linker. It currently has negative earnings. The firm also provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; mammalian manufacturing; peptide synthesis, modifications, and analytics; bioconjugate and antibody drug conjugate manufacturing; and chemical synthesis.

Seacoast Banking Corporation of Florida (NASDAQ:SBCF) Institutional Positions Chart